Objectives To update the evidence on efficacy of DMARDs (disease-modifying antirheumatic
drugs) and inform the taskforce of the 2022 update of the European Alliance of Associations …

Precision medicine (PM) is a very commonly used term that implies a highly individualized
and tailored approach to patient management. There are, however, many layers of …

The methods and results of systematic reviews should be reported in sufficient detail to allow
users to assess the trustworthiness and applicability of the review findings. The Preferred …

Chronic illnesses are associated with an increased risk of depression and anxiety.
Rheumatoid arthritis (RA) is a chronic autoimmune disease that typically causes damage to …

Globally, healthcare systems are challenged with providing appropriate care to patients with
complex care needs, multiple chronic conditions (multimorbidity) and multiple medications …

Background Early diagnosis and treatment of juvenile idiopathic arthritis (JIA) with
conventional and biologic disease-modifying anti-rheumatic drugs have vastly improved …

Rheumatoid arthritis (RA) management is driven by evidence, and new 2019 EULAR
recommendations help in refining the relevant place of different disease-modifying anti …

Objective To systematically review possible predictors of successful discontinuation of
biologic or targeted synthetic DMARDs (b/tsDMARDs) in RA patients in remission or low …

Objectives To systematically review the impact of tapering targeted therapies (bDMARDs or
JAKis) on the risk of serious infections and severe adverse events (SAEs) in patients with …

Background Psoriasis is a chronic immune-mediated inflammatory skin disease for which
biologics are effective treatments. Dose reduction (DR) of the first generation biologics …